Healthtech PR: Why Coverage Rarely Reaches the People Who Sign Contracts

A Series B health technology company announces its raise across a dozen outlets, collects a trade award, and lands an analyst mention, then closes the quarter with no new health system on the roster. The coverage performed exactly as designed. It reached investors, competitors, and recruiters. It missed the chief medical information officer and the value analysis committee, because healthtech PR built for visibility reaches almost everyone except the people who sign contracts.

The disconnect is structural rather than a failure of execution. Outlets covering funding rounds and product launches are read by the venture community and the vendor's own competitive set. The people deciding whether a health system adopts a technology read almost none of them. They evaluate vendors through a separate information system, and healthtech PR earns pipeline only when it operates inside the system rather than beside it.

This piece looks at why healthtech PR built for visibility misses the people who approve contracts, where health system buyers get vendor signal, and how to rebuild PR around contract influence. It draws on Gartner research on how B2B buyers prefer to research, EMARKETER research on AI-driven vendor discovery, and Deloitte data on health system technology decisions.

Key Takeaways

• Funding coverage reaches investors, not buyers. Raise and award coverage lands with the venture community and competitors, not the value analysis committee.
• Health systems buy on peer and analyst signal. Peer references, KLAS-style evaluations, and clinical evidence outweigh any earned media placement.
• Analyst relations often out-earns media relations. For enterprise healthtech, a strong rating enters the shortlist directly, before a sales conversation.
• Original research is an owned authority asset. One credible study feeds coverage, analyst conversations, and the sources AI tools cite.
• AI-mediated research is a new PR surface. Models cite analyst work, research, and evidence, rarely a company press release.

Who Reads Funding Coverage

Raise announcements serve a real purpose. They signal momentum to future investors, help recruiting, and reassure existing customers about a vendor's survival to renewal. None of those audiences approves a purchase. A raise announcement tells a hospital chief financial officer a vendor holds runway, which is table stakes, not a reason to buy. Occasionally it does the opposite, prompting a procurement lead to wonder how much of the new capital funds the sales motion now sitting across the table.

Award placements follow the same pattern. Most industry awards are known inside the industry and invisible outside it. A clinical informatics director evaluating a documentation tool assigns close to zero weight to a marketing award and considerable weight to whether a peer at a comparable organization runs the product and would take a call about it. The currency of health system decisions is peer evidence, and PR built around self-referential recognition trades in the wrong one.

The deeper issue is a category confusion. Health technology companies frequently inherit a consumer or general-B2B PR model built to generate reach, then apply it to a market where the buyer set numbers in the low thousands of institutions and every account has a name. Reach is the wrong objective when the entire addressable market fits on a target list, and the metrics inherited alongside it, impressions and share of voice, measure the wrong thing from the first campaign.

Where Health System Decision-Makers Get Vendor Signal

Buyer behavior reinforces the point. Gartner finds a majority of B2B buyers prefer a rep-free buying experience, researching through peers and independent sources rather than vendor-published material.

Vendor selection inside a health system runs on a specific set of inputs, and each one is a PR channel a health technology company either invests in or cedes to competitors.

• Peer references and back-channel calls. The single strongest input. Buyers trust operators at similar organizations more than any published source, and a matched reference willing to take a call outweighs a year of earned media.
• Independent analyst evaluations. KLAS, Chilmark, and comparable firms carry weight with technical and executive buyers because their assessments read as unbought, entering shortlists before a sales conversation begins.
• Professional society channels. Specialty associations, CHIME for informatics leadership, HFMA for finance, shape what their members treat as credible and where they look for options.
• Peer-reviewed clinical evidence. For any product touching care, a study in a recognized journal outperforms every earned media placement combined and survives scrutiny the others do not.
• Conference sessions rather than booths. A podium presentation by a customer, not a sponsored booth, is the format buyers register as signal rather than advertising.

Bruce Brandes, former President at care.ai, recounted one CIO’s reaction to using the platform: “This process would have taken us weeks to do this market research, and I got my shortlist within five minutes.”

None of these is a press-release channel, and all of them are reachable with the right program. This is why healthtech PR increasingly overlaps with evidence generation, analyst relations, and customer advocacy rather than announcement distribution. A serious healthcare marketing strategy treats these channels as the core of earned influence, because they are where a health system forms its shortlist.

Why Visibility Is the Wrong Objective Here

Marketing as a profession over-indexes on reach. The instinct is sound when the audience is broad and the purchase is inexpensive, and wrong when a single enterprise contract outweighs a year of smaller transactions and the decision rests with a committee of six people at a named account.

In health technology, where the addressable buyer set for many products numbers in the low thousands of institutions, a reach-first program is a liability rather than a sensible default. As buyers move vendor research toward AI assistants and independent sources, documented by EMARKETER, the press release reaches fewer of the right people each year.

Trust, not reach, is the currency, and it is built through the peer and evidence channels above. PR earns its keep as a driver of revenue and authority, not as a brand-awareness line item.

Auditing where your coverage lands versus where your buyers are?

Outcomes Rocket builds PR around the channels influencing named health system accounts.

→ Talk to a Healthtech Marketing Expert

Analyst Relations Is the Real PR for Health Technology

For enterprise health technology, an analyst relations program frequently outperforms a media relations program on pipeline. KLAS ratings enter shortlists directly. A strong evaluation, or movement in the right direction, reaches the technical and executive buyers screening vendors before a sales conversation starts. The work is unglamorous: customer satisfaction data collection, briefings, evidence submission, and sustained relationship management with the firms buyers already consult.

Companies treating analyst relations as an afterthought learn its weight late, usually when a competitor with a mediocre product and a strong rating wins a deal on the shortlist alone. Reallocating a portion of the announcement budget toward analyst engagement is one of the higher-return moves available to a health technology communications function, and one of the most neglected.

PR in the Age of AI-Mediated Vendor Research

Health system buyers increasingly begin vendor research with an AI assistant, and the sources those models cite are now a PR surface. A model summarizing options in a category pulls from analyst coverage, original research, peer-reviewed evidence, and authoritative editorial, and it rarely surfaces a company's own press releases. PR earns a place in the answer by producing and placing the material models treat as credible, then confirming the company appears when a buyer asks the obvious question.

This reframes measurement as well. A placement never reaching a buyer directly still holds value once it becomes a source a model cites when a chief information officer asks for the leading vendors in a category. Understanding how chatbots cite health information now sits inside a competent healthtech PR strategy rather than beside it as a technical curiosity.

Original Research as an Owned Authority Asset

The strongest PR asset a health technology company owns is frequently one it produces itself. Proprietary research, a benchmark study, a data set drawn from the product, an industry survey, generates earned coverage, feeds analyst conversations, supplies the statistics AI models cite, and gives the sales team a credible reason to open a conversation. A single well-designed study works across every channel buyers consult, and it positions the company as a source rather than a supplicant.

The discipline is attribution. Research earns its authority by being honest about what it measures, and a study presented as more than its sample supports damages the credibility it was built to create. Precision in how findings are framed is the difference between an asset and an embarrassment, and it is where an experienced hand earns its fee.

Rebuilding the PR Function Around Contract Influence

The shift is from announcement engine to authority engine. An announcement engine measures placements and impressions. An authority engine measures presence in the channels influencing named accounts: analyst standing, published evidence, customer references secured and activated, executive visibility in the professional societies buyers belong to, and citation in the AI tools buyers query.

For a company selling into health systems, the reallocation changes what the communications team produces, who it partners with internally, and how success reaches the board. Paired with account-based marketing, PR stops being a visibility exercise and starts influencing the specific accounts on the pipeline.

What Changes When PR Is Built for the Buyer

Funding announcements still go out, because they serve investors and recruiting. They are no longer mistaken for a commercial program. The center of gravity moves to the channels a health system decision-maker consults before a purchase, and the communications function reports on its influence over named accounts rather than its total volume of coverage. The output is smaller in raw placements and larger in pipeline, an exchange worth making for any company selling into health systems.

Frequently Asked Questions

How is healthtech PR different from general B2B PR?

General B2B PR optimizes for reach and media placements. Healthtech PR has to influence a small, defined set of institutional buyers who evaluate vendors through peer references, independent analyst firms, professional societies, and clinical evidence rather than trade media. The channels and success measures differ accordingly, and reach is the wrong objective when the entire market fits on a target list.

Do funding announcements help win health system contracts?

Rarely on their own. Raise coverage reaches investors, competitors, and recruits, and signals runway. Health system buyers weigh peer references and analyst standing far more heavily, and occasionally read heavy sales-stage funding as a cost destined to be passed to them.

What channels influence health system vendor selection?

Peer references and back-channel calls, independent analyst evaluations such as KLAS, professional society channels including CHIME and HFMA, peer-reviewed clinical evidence, and customer-led conference sessions. These carry more weight with an institutional buyer than any earned media placement.

How does analyst relations fit into healthtech PR?

For enterprise health technology, analyst relations often drives more pipeline than media relations. Ratings from firms like KLAS enter shortlists directly and reach technical and executive buyers before a sales conversation, which makes sustained analyst engagement one of the highest-return communications investments available.

How should healthtech PR support AI-driven vendor research?

Buyers increasingly start with AI assistants citing analyst coverage, original research, and peer-reviewed evidence rather than press releases. PR earns a place in those answers by producing and placing credible source material, including proprietary research, which makes AI citation a measurable PR objective rather than a technical afterthought.

Ready to make your PR reach the people who sign contracts?

Outcomes Rocket aligns earned influence, analyst relations, and evidence into a program reaching buyers.

→ Book a Strategy Session

‍